Better Medicines for HIV/AIDS
Official title: Developing Selective Inhibitors and Probes for Concentrative Nucleoside Transporters
Funded at Rosalind Franklin Univ of Medicine & Sci · NIH-11146560 · Data updated 2026-11-12
This work aims to create new and safer versions of current HIV/AIDS medicines by targeting specific transporters in the body.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rosalind Franklin Univ of Medicine & Sci NIH-funded |
| Lab location | 1 site (North Chicago, United States) |
| Project start | August 1, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $176,196 |
| NIH project number | 5R21AI181894-02 |
| Project ID | NIH-11146560 on NIH RePORTER |
Who could benefit from this research
✓Could help
This foundational work is for patients living with HIV/AIDS who currently take or may need nucleoside reverse transcriptase inhibitors (NRTIs) and experience or are at risk for drug-related toxicities.
✕Less likely to help
Patients who do not have HIV/AIDS or are not treated with nucleoside-based therapies would not directly benefit from this specific research.
What this research studies
Many current HIV/AIDS medications, while effective, can cause serious side effects like kidney problems or weight gain. This project focuses on tiny structures in our bodies called nucleoside transporters, which move these medicines around. By understanding how these transporters work, we hope to design new medicines that are just as effective but cause fewer unwanted side effects. Our goal is to make HIV/AIDS treatments safer and more comfortable for patients.
Why it matters
Potential benefit: If successful, this work could lead to new HIV/AIDS medications that are more tolerable and have fewer severe side effects for patients.
How similar studies have gone: While the concept of optimizing existing therapies is established, this specific approach of developing selective inhibitors for concentrative nucleoside transporters to reduce HIV/AIDS drug toxicity is a novel area of focus.
Where this research is happening
-
Rosalind Franklin Univ of Medicine & Sci
North Chicago, United States Active
Researchers
- Principal investigator: Buolamwini, John K — Rosalind Franklin Univ of Medicine & Sci
- Study coordinator: Buolamwini, John K
Related research
Other NIH-funded projects on the same topics.
-
Improving Diabetic Foot Ulcer Offloading with User-Friendly Cast Walker Design
A small pilot study to see how different removable cast walker designs affect daily use and healing of diabetic foot ulcers.
-
How the liver's ketone production affects muscle loss and recovery in pancreatic cancer
This project looks at whether helping the liver make ketones can prevent muscle wasting and aid recovery for people with pancreatic cancer.
-
How the amygdala and social behavior develop during adolescence
Studying how experiences in adolescence shape the brain’s social circuits to help understand and prevent lifelong social difficulties.
-
Targeting Vasopressin and Oxytocin Receptors to Treat Anxiety and Fear
Researchers are testing how brain chemical signals related to vasopressin and oxytocin in the BNST region affect fear and anxiety, with the goal of identifying new ways to treat anxiety disorders.
-
Role of TAM receptors in humoral immunity and malaria
A doctor-science team is studying how a specific immune pathway (TAM receptors on B cells) affects antibody responses to malaria and whether blocking this pathway could improve immunity.
-
Understanding rejection sensitivity and mental health in LGBTQ+ teens
A long-term study follows LGBTQ+ adolescents to see how worries about rejection affect their mood and mental well-being.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.